Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study
Abstract Background There is little descriptive data on Stenotrophomonas maltophilia hospital-acquired pneumonia (HAP) in critically ill patients. The optimal modalities of antimicrobial therapy remain to be determined. Our objective was to describe the epidemiology and prognostic factors associated...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-11-01
|
Series: | Critical Care |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13054-019-2649-5 |
id |
doaj-02d21c1dadd645f7b4da41b61f8e7b49 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Philippe Guerci Hugo Bellut Mokhtar Mokhtari Julie Gaudefroy Nicolas Mongardon Claire Charpentier Guillaume Louis Parvine Tashk Clément Dubost Stanislas Ledochowski Antoine Kimmoun Thomas Godet Julien Pottecher Jean-Marc Lalot Emmanuel Novy David Hajage Adrien Bouglé AZUREA research network |
spellingShingle |
Philippe Guerci Hugo Bellut Mokhtar Mokhtari Julie Gaudefroy Nicolas Mongardon Claire Charpentier Guillaume Louis Parvine Tashk Clément Dubost Stanislas Ledochowski Antoine Kimmoun Thomas Godet Julien Pottecher Jean-Marc Lalot Emmanuel Novy David Hajage Adrien Bouglé AZUREA research network Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study Critical Care Hospital-acquired pneumonia Stenotrophomonas maltophilia Intensive care Antimicrobial therapy Combination therapy |
author_facet |
Philippe Guerci Hugo Bellut Mokhtar Mokhtari Julie Gaudefroy Nicolas Mongardon Claire Charpentier Guillaume Louis Parvine Tashk Clément Dubost Stanislas Ledochowski Antoine Kimmoun Thomas Godet Julien Pottecher Jean-Marc Lalot Emmanuel Novy David Hajage Adrien Bouglé AZUREA research network |
author_sort |
Philippe Guerci |
title |
Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study |
title_short |
Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study |
title_full |
Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study |
title_fullStr |
Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study |
title_full_unstemmed |
Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study |
title_sort |
outcomes of stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study |
publisher |
BMC |
series |
Critical Care |
issn |
1364-8535 |
publishDate |
2019-11-01 |
description |
Abstract Background There is little descriptive data on Stenotrophomonas maltophilia hospital-acquired pneumonia (HAP) in critically ill patients. The optimal modalities of antimicrobial therapy remain to be determined. Our objective was to describe the epidemiology and prognostic factors associated with S. maltophilia pneumonia, focusing on antimicrobial therapy. Methods This nationwide retrospective study included all patients admitted to 25 French mixed intensive care units between 2012 and 2017 with hospital-acquired S. maltophilia HAP during intensive care unit stay. Primary endpoint was time to in-hospital death. Secondary endpoints included microbiologic effectiveness and antimicrobial therapeutic modalities such as delay to appropriate antimicrobial treatment, mono versus combination therapy, and duration of antimicrobial therapy. Results Of the 282 patients included, 84% were intubated at S. maltophilia HAP diagnosis for duration of 11 [5–18] days. The Simplified Acute Physiology Score II was 47 [36–63], and the in-hospital mortality was 49.7%. Underlying chronic pulmonary comorbidities were present in 14.1% of cases. Empirical antimicrobial therapy was considered effective on S. maltophilia according to susceptibility patterns in only 30% of cases. Delay to appropriate antimicrobial treatment had, however, no significant impact on the primary endpoint. Survival analysis did not show any benefit from combination antimicrobial therapy (HR = 1.27, 95%CI [0.88; 1.83], p = 0.20) or prolonged antimicrobial therapy for more than 7 days (HR = 1.06, 95%CI [0.6; 1.86], p = 0.84). No differences were noted in in-hospital death irrespective of an appropriate and timely empiric antimicrobial therapy between mono- versus polymicrobial S. maltophilia HAP (p = 0.273). The duration of ventilation prior to S. maltophilia HAP diagnosis and ICU length of stay were shorter in patients with monomicrobial S. maltophilia HAP (p = 0.031 and p = 0.034 respectively). Conclusions S. maltophilia HAP occurred in severe, long-stay intensive care patients who mainly required prolonged invasive ventilation. Empirical antimicrobial therapy was barely effective while antimicrobial treatment modalities had no significant impact on hospital survival. Trial registration clinicaltrials.gov, NCT03506191 |
topic |
Hospital-acquired pneumonia Stenotrophomonas maltophilia Intensive care Antimicrobial therapy Combination therapy |
url |
http://link.springer.com/article/10.1186/s13054-019-2649-5 |
work_keys_str_mv |
AT philippeguerci outcomesofstenotrophomonasmaltophiliahospitalacquiredpneumoniainintensivecareunitanationwideretrospectivestudy AT hugobellut outcomesofstenotrophomonasmaltophiliahospitalacquiredpneumoniainintensivecareunitanationwideretrospectivestudy AT mokhtarmokhtari outcomesofstenotrophomonasmaltophiliahospitalacquiredpneumoniainintensivecareunitanationwideretrospectivestudy AT juliegaudefroy outcomesofstenotrophomonasmaltophiliahospitalacquiredpneumoniainintensivecareunitanationwideretrospectivestudy AT nicolasmongardon outcomesofstenotrophomonasmaltophiliahospitalacquiredpneumoniainintensivecareunitanationwideretrospectivestudy AT clairecharpentier outcomesofstenotrophomonasmaltophiliahospitalacquiredpneumoniainintensivecareunitanationwideretrospectivestudy AT guillaumelouis outcomesofstenotrophomonasmaltophiliahospitalacquiredpneumoniainintensivecareunitanationwideretrospectivestudy AT parvinetashk outcomesofstenotrophomonasmaltophiliahospitalacquiredpneumoniainintensivecareunitanationwideretrospectivestudy AT clementdubost outcomesofstenotrophomonasmaltophiliahospitalacquiredpneumoniainintensivecareunitanationwideretrospectivestudy AT stanislasledochowski outcomesofstenotrophomonasmaltophiliahospitalacquiredpneumoniainintensivecareunitanationwideretrospectivestudy AT antoinekimmoun outcomesofstenotrophomonasmaltophiliahospitalacquiredpneumoniainintensivecareunitanationwideretrospectivestudy AT thomasgodet outcomesofstenotrophomonasmaltophiliahospitalacquiredpneumoniainintensivecareunitanationwideretrospectivestudy AT julienpottecher outcomesofstenotrophomonasmaltophiliahospitalacquiredpneumoniainintensivecareunitanationwideretrospectivestudy AT jeanmarclalot outcomesofstenotrophomonasmaltophiliahospitalacquiredpneumoniainintensivecareunitanationwideretrospectivestudy AT emmanuelnovy outcomesofstenotrophomonasmaltophiliahospitalacquiredpneumoniainintensivecareunitanationwideretrospectivestudy AT davidhajage outcomesofstenotrophomonasmaltophiliahospitalacquiredpneumoniainintensivecareunitanationwideretrospectivestudy AT adrienbougle outcomesofstenotrophomonasmaltophiliahospitalacquiredpneumoniainintensivecareunitanationwideretrospectivestudy AT azurearesearchnetwork outcomesofstenotrophomonasmaltophiliahospitalacquiredpneumoniainintensivecareunitanationwideretrospectivestudy |
_version_ |
1724421425832394752 |
spelling |
doaj-02d21c1dadd645f7b4da41b61f8e7b492020-11-25T04:09:53ZengBMCCritical Care1364-85352019-11-0123111310.1186/s13054-019-2649-5Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective studyPhilippe Guerci0Hugo Bellut1Mokhtar Mokhtari2Julie Gaudefroy3Nicolas Mongardon4Claire Charpentier5Guillaume Louis6Parvine Tashk7Clément Dubost8Stanislas Ledochowski9Antoine Kimmoun10Thomas Godet11Julien Pottecher12Jean-Marc Lalot13Emmanuel Novy14David Hajage15Adrien Bouglé16AZUREA research networkDepartment of Anaesthesiology and Critical Care Medicine, Institut Lorrain du Coeur et des Vaisseaux, University Hospital of Nancy-BraboisSorbonne Université, Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Anaesthesiology and Critical Care Medicine, Institute of Cardiology, Pitié-Salpêtrière HospitalDepartment of Anaesthesiology and Critical Care Medicine, Institut Lorrain du Coeur et des Vaisseaux, University Hospital of Nancy-BraboisService d’Anesthésie-Réanimation Chirurgicale, Hôpital Hautepierre, Hôpitaux Universitaires de StrasbourgService d’Anesthésie-Réanimation, Hôpital Henri Mondor, DMU CARE, Assistance Publique - Hôpitaux de Paris (AP-HP), Inserm U955 équipe 3, Université Paris-Est CréteilRéanimation Chirurgicale Polyvalente, Hôpital Central, Centre Hospitalier Universitaire de NancyRéanimation polyvalente, Hôpital de Mercy, CHR Metz-ThionvilleService d’Anesthésie-Réanimation, Hôpital Bichat-Claude Bernard, Assistance Publique - Hôpitaux de Paris (AP-HP)Réanimation polyvalente, Hôpital d’Instruction des Armées (HIA) BéginService de Réanimation Polyvalente, Groupement Hospitalier Nord Dauphiné- Centre Hospitalier Pierre OudotRéanimation Médicale, Institut Lorrain du Cœur et des Vaisseaux, CHU Nancy-BraboisRéanimation Adultes et Soins Continus, Pôle de Médecine Péri-opératoire, Hôpital Estaing, Centre Hospitalier Universitaire de Clermont-FerrandService d’Anesthésie-Réanimation Chirurgicale, Hôpital Hautepierre, Hôpitaux Universitaires de StrasbourgService d’Anesthésie-Réanimation, Réanimation polyvalente, Centre Hospitalier Emile DurkheimDepartment of Anaesthesiology and Critical Care Medicine, Institut Lorrain du Coeur et des Vaisseaux, University Hospital of Nancy-BraboisDépartement Biostatistique Santé Publique Et Information Médicale, Unité de Recherche Clinique PSL-CFX, Centre de Pharmacoépidémiologie (Cephepi), Sorbonne Université, INSERM, Institut Pierre Louis de Santé Publique, Equipe Pharmacoépidémiologie et évaluation des soins, AP-HP, Hôpital Pitié-Salpêtrière, CIC-1421Sorbonne Université, Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Anaesthesiology and Critical Care Medicine, Institute of Cardiology, Pitié-Salpêtrière HospitalAbstract Background There is little descriptive data on Stenotrophomonas maltophilia hospital-acquired pneumonia (HAP) in critically ill patients. The optimal modalities of antimicrobial therapy remain to be determined. Our objective was to describe the epidemiology and prognostic factors associated with S. maltophilia pneumonia, focusing on antimicrobial therapy. Methods This nationwide retrospective study included all patients admitted to 25 French mixed intensive care units between 2012 and 2017 with hospital-acquired S. maltophilia HAP during intensive care unit stay. Primary endpoint was time to in-hospital death. Secondary endpoints included microbiologic effectiveness and antimicrobial therapeutic modalities such as delay to appropriate antimicrobial treatment, mono versus combination therapy, and duration of antimicrobial therapy. Results Of the 282 patients included, 84% were intubated at S. maltophilia HAP diagnosis for duration of 11 [5–18] days. The Simplified Acute Physiology Score II was 47 [36–63], and the in-hospital mortality was 49.7%. Underlying chronic pulmonary comorbidities were present in 14.1% of cases. Empirical antimicrobial therapy was considered effective on S. maltophilia according to susceptibility patterns in only 30% of cases. Delay to appropriate antimicrobial treatment had, however, no significant impact on the primary endpoint. Survival analysis did not show any benefit from combination antimicrobial therapy (HR = 1.27, 95%CI [0.88; 1.83], p = 0.20) or prolonged antimicrobial therapy for more than 7 days (HR = 1.06, 95%CI [0.6; 1.86], p = 0.84). No differences were noted in in-hospital death irrespective of an appropriate and timely empiric antimicrobial therapy between mono- versus polymicrobial S. maltophilia HAP (p = 0.273). The duration of ventilation prior to S. maltophilia HAP diagnosis and ICU length of stay were shorter in patients with monomicrobial S. maltophilia HAP (p = 0.031 and p = 0.034 respectively). Conclusions S. maltophilia HAP occurred in severe, long-stay intensive care patients who mainly required prolonged invasive ventilation. Empirical antimicrobial therapy was barely effective while antimicrobial treatment modalities had no significant impact on hospital survival. Trial registration clinicaltrials.gov, NCT03506191http://link.springer.com/article/10.1186/s13054-019-2649-5Hospital-acquired pneumoniaStenotrophomonas maltophiliaIntensive careAntimicrobial therapyCombination therapy |